Delivery Order SPE2DB22D1002-SPE2DB25FLFJ8
Award Date 7/28/25
Potential Completion Date 8/18/25
Potential Value $1.6K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Xolair 300 mg/2 mL autoinjector units valued at $3,188.32. This firm fixed price delivery order, with an ultimate completion date of August 12, 2025, represents a non-set-aside competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $3,188.32 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for Xolair 300 mg/2 ml auto-injector units, with completion targeted for August 11, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered from AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $10,393.14 to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 mL syringes on July 22, 2025. This firm fixed-price, non-set-aside contract is scheduled for completion by August 12, 2025, with performance occurring at the vendor's location in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody therapeutic used in the treatment of moderate-to-severe asthma and other allergic conditions, representing a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of XOLAIR 300 mg/2 ml auto-injector prefilled syringes. This competitive award, valued at $3,188.32 with firm fixed pricing, is scheduled for completion by August 18, 2025. The contract represents a direct delivery order under AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. As a pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a $3,601.70 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for Xolair 150 mg/mL syringes, with an ultimate completion date of August 13, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $3,601.70 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes. This competitively awarded, firm fixed-price contract was issued on July 23, 2025, with an ultimate completion date of August 13, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. XOLAIR (omalizumab) is a monoclonal antibody...
- The Defense Logistics Agency awarded a delivery order valued at $7,203.40 to AmerisourceBergen Drug Corp for XOLAIR 150 MG/1.2 ML Powder vials under a firm fixed-price contract. The award was made on July 21, 2025, with an ultimate completion date of August 11, 2025. This is a non-set-aside, competitively awarded delivery order that will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody therapy commonly used for treating...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on July 28, 2025, valued at $6,376.64 for Xolair 300 mg/2 mL auto-injector units. This firm fixed price, competitive delivery order is funded by the Defense Logistics Agency (DLA) and will be performed at the awardee's Conshohocken facility, with an ultimate completion date of August 18, 2025. No set-aside provisions were applied to this award. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Xolair 300 mg/2 mL auto-injector units. This competitively awarded, non-set-aside contract has a ceiling value of $63,766.40 with a firm fixed price structure and an ultimate completion date of August 12, 2025. The place of performance is the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xolair 300 mg/2 mL auto-injectors with a ceiling value of $1,594.16 and a firm fixed price structure. The order is scheduled for completion by August 11, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued under a non-set-aside, competitive procurement process and represents a continuation of the pharmaceutical...